menu
    • menu

    Company profile for Aucta Pharmaceuticals

    Aucta Pharmaceuticals-PSE
    News
    Aucta debuts generic Vimpat

    11 Mar 2024

    // DRUG STORE NEWS

    Aucta Pharma Launches First Once-Daily Lacosamide ER Capsule

    26 Feb 2024

    // PR NEWSWIRE

    Aucta announced FDA approval of a generic version of Trileptal oral suspension

    05 Dec 2022

    // PR NEWSWIRE

    DATA COMPILATION
    #PharmaFlow

    Aucta Read More

    Contact Supplier

    Website

    BMWS24

    Not Confirmed

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    radio-compass-blog/medical-breakthroughs-in-2024-alzheimer-s-schizophrenia-copd-mash-see-pathbreaking-treatments

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    Aucta is a global brand that creates better products from proven molecules.

    Related CompaniesRelated Companies

    About

    Aucta Pharmaceuticals is an emerging drug product development company focusing on new branded 505(b)(2) products and technology platform-based niche generics. Aucta adopts a branded/generic hybrid model, generating both near-term product revenue and mid- to long-term investment return, aiming to become a significant specialty pharma player in the United States and China marketplace. We focus on developing enhanced products for patients with a therapeutic focus on CNS disorders, as well as Ophthalmics, and Inhalation therapies.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Aucta PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    71 Suttons Lane, Piscataway, NJ 08854
    Telephone
    Telephone
    +1 7326400030
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.auctapharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/aucta-pharmaceuticals/
    youtube
    YouTube
    Twitter
    Twitter
    Contact Info
    Others

    China:
    Address:
    Room 301, Building #2, No. 3377 Kangxin Road.
    SIMZ Pudong, Shanghai, P.R.
    China Zip Code: 201318
    Phone: +862158585606
    Fax: +862158585607

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    CPhI India 2024

    CPhI India 2024

    Not Confirmed

    envelop Contact Supplier

    CPhI India 2024

    Post an Enquiry

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    CORPORATE CONTENT #SupplierSpotlight

    Product List 2023

    read-more

      https://www.pharmacompass.com/pdf/party/content/aucta-pharmaceuticals-llc-party-content-46886.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Corporate Presentation

    read-more

      https://www.pharmacompass.com/pdf/party/content/aucta-pharmaceuticals-llc-party-content-1623650142.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    NEWS #PharmaBuzz

    read-more
    read-more
    Aucta debuts generic Vimpat
    Aucta debuts generic Vimpat

    11 Mar 2024

    // DRUG STORE NEWS

    https://drugstorenews.com/aucta-debuts-generic-vimpat

    DRUG STORE NEWS
    11 Mar 2024
    Share Share
    Aucta Pharma Launches First Once-Daily Lacosamide ER Capsule
    Aucta Pharma Launches First Once-Daily Lacosamide ER Capsule

    26 Feb 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/aucta-pharmaceuticals-inc-aucta-pharmaceuticals-launches-motpoly-xr-lacosamide-extended-release-capsules-c-v-the-first-and-only-once-daily-formulation-of-lacosamide-302070783.html

    PR NEWSWIRE
    26 Feb 2024
    Share Share
    Aucta announced FDA approval of a generic version of Trileptal oral suspension
    Aucta announced FDA approval of a generic version of Trileptal oral suspension

    05 Dec 2022

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/aucta-announced-fda-approval-of-a-generic-version-of-trileptaloxcarbazepine-oral-suspension-301694327.html#:~:text=PISCATAWAY%2C%20N.J.%2C%20Dec.,this%20product%20in%20early%202023.

    PR NEWSWIRE
    05 Dec 2022
    Share Share
    Aucta announces FDA approval of a generic version of Perforomist Inhalation
    Aucta announces FDA approval of a generic version of Perforomist Inhalation

    01 Dec 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/aucta-announces-fda-approval-of-a-generic-version-of-perforomist-formoterol-fumarate-inhalation-solution-301691187.html

    PRNEWSWIRE
    01 Dec 2022
    Share Share
    Aucta's Generic Oxcarbazepine Receives Approval in the U.S.
    Aucta's Generic Oxcarbazepine Receives Approval in the U.S.

    30 Nov 2022

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215332

    FDA
    30 Nov 2022
    Share Share
    Aucta's Generic Formoterol Fumarate Receives Approval in the U.S.
    Aucta's Generic Formoterol Fumarate Receives Approval in the U.S.

    25 Nov 2022

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216486

    FDA
    25 Nov 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search